Briefly informed "

> Batch recall of amiodarone 150 mg iv Carino - During routine check of retained samples from batches BD36 and BD37 of the preparation amiodarone 150 mg i.v. Carino (PZN 7308043), small amounts of crystallization were found in one ampoule. For security reasons, Carinopharm GmbH asks you to check existing stocks of the batches mentioned and to send them back or have them picked up (Carinopharm GmbH, Bahnhofstraße 18, 31 008 Elze, phone: 05068 93333 31).

Market approval for Gadovist ® 1.0 in children aged two and over - Bayer HealthCare has successfully completed the approval process for the Gadovist 1.0 contrast agent for use in children aged two to six completed. Gadovist has been registered for children from the age of seven since 2009. Germany will start immediately with the market launch of Gadovist in the new indication.

Gadovist is for the most frequently undertaken contrast-enhanced magnetic resonance imaging examinations are permitted. This includes images of the central nervous system, the liver and the kidneys as well as the vascular representation.

New: Edarbi antihypertensive agent ® (azilsartan) - Takeda-Pharma approves angiotensin to be dosed once day Receptor blockers (angiotensin II antagonist) Edarbi (azilsartan) known for the treatment of essential hypertension in adults. The recommendation was based, among other things, on data from seven phase 3 studies in which almost 6,000 patients were included. The highest dose of azilsartan tested (80 mg / day) showed significantly greater decrease in mean 24-hour blood pressure than the highest tested dose of the angiotensin receptor blockers olmesartan (40 mg / day) and valsartan (320 mg / day). Day) and the ACE inhibitor ramipril (10 mg / day). The side effects associated with azilsartan were mild or moderate according to the manufacturer, with an overall incidence at the placebo level. The most common observations were dizziness, an increase in creatine phosphokinase and diarrhea.

Buccolam ® as an acute medication in the pediatric field - ab Buccolam (midazolam, solution for use in the oral cavity, ViroPharma) is available immediately for the emergency treatment of prolonged, acute seizures in infants, toddlers, children and adolescents aged three months to under 18 years. Briefly informed "

> Batch recall of amiodarone 150 mg iv Carino - During routine check of retained samples from batches BD36 and BD37 of the preparation amiodarone 150 mg i.v. Carino (PZN 7308043), small amounts of crystallization were found in one ampoule. For security reasons, Carinopharm GmbH asks you to check existing stocks of the batches mentioned and to send them back or have them picked up (Carinopharm GmbH, Bahnhofstraße 18, 31 008 Elze, phone: 05068 93333 31).

Market approval for Gadovist ® 1.0 in children aged two and over - Bayer HealthCare has successfully completed the approval process for the Gadovist 1.0 contrast agent for use in children aged two to six completed. Gadovist has been registered for children from the age of seven since 2009. Germany will start immediately with the market launch of Gadovist in the new indication.

Gadovist is for the most frequently undertaken contrast-enhanced magnetic resonance imaging examinations are permitted. This includes images of the central nervous system, the liver and the kidneys as well as the vascular representation.

New: Edarbi antihypertensive agent ® (azilsartan) - Takeda-Pharma approves angiotensin to be dosed once day Receptor blockers (angiotensin II antagonist) Edarbi (azilsartan) known for the treatment of essential hypertension in adults. The recommendation was based, among other things, on data from seven phase 3 studies in which almost 6,000 patients were included. The highest dose of azilsartan tested (80 mg / day) showed significantly greater decrease in mean 24-hour blood pressure than the highest tested dose of the angiotensin receptor blockers olmesartan (40 mg / day) and valsartan (320 mg / day). Day) and the ACE inhibitor ramipril (10 mg / day). The side effects associated with azilsartan were mild or moderate according to the manufacturer, with an overall incidence at the placebo level. The most common observations were dizziness, an increase in creatine phosphokinase and diarrhea.

Buccolam ® as an acute medication in the pediatric field - ab Buccolam (midazolam, solution for use in the oral cavity, ViroPharma) is available immediately for the emergency treatment of prolonged, acute seizures in infants, toddlers, children and adolescents aged three months to under 18 years.Infants between three and six months of age should be treated in clinic with monitoring facilities and appropriate resuscitation equipment. Buccolam may only be administered by parents / carers if the patient has been diagnosed with epilepsy.

Sitagliptin approved for all stages of renal insufficiency - Sitagliptin (Berlin-Chemie) has the approval for use in type 2 diabetic patients with moderate to severe (including end-stage) renal disease. The dosage depends on the kidney function:

  • 1 × 50 mg daily for moderate renal insufficiency (creatinine clearance: 30 to 50 ml / min),
  • 1 × 25 mg daily for severe to end-stage renal failure (creatinine clearance
8 0